DYN - CIK 0001818794
Dyne Therapeutics, Inc. trades as DYN and has a market capitalization of $2.91 B, making it the #1828 largest US-listed company by market value. This page tracks Dyne Therapeutics, Inc. through 710 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider sale notice | 144 | 2026-05-13 |
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval | Dyne Therapeutics, Inc.
Dyne Therapeutics to Participate in Upcoming Investor Conferences | Dyne Therapeutics, Inc.
The largest companies sharing Dyne Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Dyne Therapeutics, Inc. (DYN) has a market capitalization of $2.91 B as of 2026-06-10, ranking #1828 among US-listed companies.
In its latest fiscal year Dyne Therapeutics, Inc. reported a net loss of $446.20.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Dyne Therapeutics, Inc.